LIFE - ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

ATyr Pharma (LIFE) has announced topline results from its Phase 2 trial evaluating its its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation. The trial met its primary endpoint of safety, demonstrating that a single, intravenous dose of ATYR1923 was generally safe and well-tolerated in both the 1.0 and 3.0 mg/kg treatment groups, with no drug-related serious adverse events.Patients who received the 3.0 mg/kg dose of ATYR1923 experienced a median time to recovery of 5.5 days compared to 6 days in placebo group. In addition, 83% of patients achieved recovery by day 6, vs. 56% in the placebo arm. Patients in the 1.0 mg/kg treatment arm experienced a median time to recovery of 7 days.Two deaths were observed in the study, both in the 1.0 mg/kg treatment arm, which were deemed not related to ATYR1923 by an independent data safety monitoring

For further details see:

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study